Daiichi Sankyo and Servier Canada in edoxaban marketing deal

27 June 2016

Japanese drug major Daiichi Sankyo (TYO: 4568) has entered into a strategic partnership with the Canadian subsidiary of French privately-held drugmaker Servier for the marketing of the stroke prevention drug edoxaban.

Servier Canada will market the drug for use in patients with atrial fibrillation and venous thromboembolism (VTE) in the North American country, if it receives approval from the Canadian health authority.

Daiichi Sankyo filed a New Drug Submission for edoxaban with the Health Products and Food Branch of Health Canada in August 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK